1. The use of specific radiotracers called radiopharmaceuticals for imaging organ function and disease states is a unique capability of nuclear medicine. Unlike other imaging modalities such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and Ultrasonography (US), nuclear medicine procedures are capable of mapping physiological function and metabolic activity and thereby giving mo...

PURPOSE This short review aims to cover the more recent and promising developments of carbon-11 (11C) labeling radiochemistry and its utility in the production of novel radiopharmaceuticals, with special emphasis on methods that have the greatest potential to be translated for clinical positron emission tomography (PET) imaging. METHODS A survey of the literature was undertaken to identify ar...

In the continuous search for earlier diagnosis and improved therapeutic modalities against cancer, based on our constantly increasing knowledge of cancer biology, aptamers hold the promise to expand on current antibody success, but overcoming some of the problems faced with antibodies as therapeutic or delivery agents in cancer. However, as the first aptamer reached the market as an inhibitor a...

In the last one and half decade, Lu has emerged as one of the most important and useful radionuclides for the development of a wide variety of targeted radiotherapy agents owing to its suitable nuclear decay characteristics, comparatively longer half-life and production feasibility using medium flux research reactors. Radiopharmaceuticals Division (RPhD), BARC has done pioneering work in the fi...

Patients undergoing nuclear medicine procedures for cancer therapy are administered radiopharmaceuticals that emit various types of radiation. Because radiation has differential delivery to and uptake by cells in tissue, radiation exposures are often highly nonuniform. Some cell populations in a tissue may contain widely different amounts of radioactivity, whereas other cell populations in the ...

Introduction In nuclear medicine, diagnostic imaging displays the metabolic function of the human body. The radiopharmaceuticals enable cancer imaging as unbound isotopes or simple compounds, non target tracers, target tracers and target cancer radiopharmaceuticals (1). Molecular imaging strategies of PET radiopharmaceuticals and combined technology of PET-CT have a major role in oncology today...

Abstract. The goal of this project is to determine the absorbed dose of radiation to a patient using 99mTc-MAA as a tracer for a lung scan using the MIRD formula accounting only for the radiation dose contributed by the target organ. The radiation dose for other organs to the target organ is considered negligible as the uptake of 99mTc-MAA from other organs is less than 1%. In addition to calcu...

Secure determination of the binding of 99mTc-radiopharmaceuticals to plasma (P) and blood cell (BC) constituents can help to understand the biodistribution of radiophamaceuticals. The reported precipitation studies of blood with radiopharmaceuticals have shown that the results can not be easily compared between studies. We decided to determine the "gold standard" concentration of trichloroaceti...

Positron emission tomography (PET) imaging has emerged as an important clinical tool for cancer management, and specifically targeted radiopharmaceuticals play critical roles on PET molecular imaging. Solid cancers have highly complex and heterogeneous microenvironment, this review focused on those microenvironmental factors such as hypoxia, proliferation and perfusion and, accordingly, a novel...